世界の自己免疫性溶血性貧血治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Autoimmune Hemolytic Anemia Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12076 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、自己免疫性溶血性貧血治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。自己免疫性溶血性貧血治療薬の種類別市場規模（コルチコステロイド、モノクローナル抗体、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・自己免疫性溶血性貧血治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Amneal Pharmaceuticals Inc、Baxter International Inc、F. Hoffmann-La Roche Ltd、Incyte Corp、Kezar Life Sciences Inc、Pfizer Inc、Rigel Pharmaceuticals Inc、Sanofi、Teva Pharmaceutical Industries Ltd、Horizo​​n、Genentech、Zydus Cadila、Concord Biotech ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：コルチコステロイド、モノクローナル抗体、その他 ・用途別分析2016年-2026年：病院薬局、小売薬局、オンライン薬局 ・自己免疫性溶血性貧血治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・自己免疫性溶血性貧血治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・自己免疫性溶血性貧血治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・自己免疫性溶血性貧血治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・自己免疫性溶血性貧血治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Autoimmune Hemolytic Anemia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Autoimmune Hemolytic Anemia Therapeutics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Autoimmune Hemolytic Anemia Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Autoimmune Hemolytic Anemia Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Corticosteroids
Monoclonal Antibodies
Others

Market segment by Application, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market segment by players, this report covers
Amneal Pharmaceuticals Inc
Baxter International Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Kezar Life Sciences Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
Sanofi
Teva Pharmaceutical Industries Ltd
Horizo​​n
Genentech
Zydus Cadila
Concord Biotech

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Autoimmune Hemolytic Anemia Therapeutics
1.2 Classification of Autoimmune Hemolytic Anemia Therapeutics by Type
1.2.1 Overview: Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Type in 2020
1.2.3 Corticosteroids
1.2.4 Monoclonal Antibodies
1.2.5 Others
1.3 Global Autoimmune Hemolytic Anemia Therapeutics Market by Application
1.3.1 Overview: Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Autoimmune Hemolytic Anemia Therapeutics Market Size & Forecast
1.5 Global Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast by Region
1.5.1 Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Autoimmune Hemolytic Anemia Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Autoimmune Hemolytic Anemia Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Autoimmune Hemolytic Anemia Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Autoimmune Hemolytic Anemia Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Autoimmune Hemolytic Anemia Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Autoimmune Hemolytic Anemia Therapeutics Market Drivers
1.6.2 Autoimmune Hemolytic Anemia Therapeutics Market Restraints
1.6.3 Autoimmune Hemolytic Anemia Therapeutics Trends Analysis
2 Company Profiles
2.1 Amneal Pharmaceuticals Inc
2.1.1 Amneal Pharmaceuticals Inc Details
2.1.2 Amneal Pharmaceuticals Inc Major Business
2.1.3 Amneal Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.1.4 Amneal Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Amneal Pharmaceuticals Inc Recent Developments and Future Plans
2.2 Baxter International Inc
2.2.1 Baxter International Inc Details
2.2.2 Baxter International Inc Major Business
2.2.3 Baxter International Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.2.4 Baxter International Inc Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Baxter International Inc Recent Developments and Future Plans
2.3 F. Hoffmann-La Roche Ltd
2.3.1 F. Hoffmann-La Roche Ltd Details
2.3.2 F. Hoffmann-La Roche Ltd Major Business
2.3.3 F. Hoffmann-La Roche Ltd Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.3.4 F. Hoffmann-La Roche Ltd Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.4 Incyte Corp
2.4.1 Incyte Corp Details
2.4.2 Incyte Corp Major Business
2.4.3 Incyte Corp Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.4.4 Incyte Corp Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Incyte Corp Recent Developments and Future Plans
2.5 Kezar Life Sciences Inc
2.5.1 Kezar Life Sciences Inc Details
2.5.2 Kezar Life Sciences Inc Major Business
2.5.3 Kezar Life Sciences Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.5.4 Kezar Life Sciences Inc Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Kezar Life Sciences Inc Recent Developments and Future Plans
2.6 Pfizer Inc
2.6.1 Pfizer Inc Details
2.6.2 Pfizer Inc Major Business
2.6.3 Pfizer Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.6.4 Pfizer Inc Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Pfizer Inc Recent Developments and Future Plans
2.7 Rigel Pharmaceuticals Inc
2.7.1 Rigel Pharmaceuticals Inc Details
2.7.2 Rigel Pharmaceuticals Inc Major Business
2.7.3 Rigel Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.7.4 Rigel Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Rigel Pharmaceuticals Inc Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.8.4 Sanofi Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Teva Pharmaceutical Industries Ltd
2.9.1 Teva Pharmaceutical Industries Ltd Details
2.9.2 Teva Pharmaceutical Industries Ltd Major Business
2.9.3 Teva Pharmaceutical Industries Ltd Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.9.4 Teva Pharmaceutical Industries Ltd Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.10 Horizo​​n
2.10.1 Horizo​​n Details
2.10.2 Horizo​​n Major Business
2.10.3 Horizo​​n Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.10.4 Horizo​​n Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Horizo​​n Recent Developments and Future Plans
2.11 Genentech
2.11.1 Genentech Details
2.11.2 Genentech Major Business
2.11.3 Genentech Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.11.4 Genentech Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Genentech Recent Developments and Future Plans
2.12 Zydus Cadila
2.12.1 Zydus Cadila Details
2.12.2 Zydus Cadila Major Business
2.12.3 Zydus Cadila Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.12.4 Zydus Cadila Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Zydus Cadila Recent Developments and Future Plans
2.13 Concord Biotech
2.13.1 Concord Biotech Details
2.13.2 Concord Biotech Major Business
2.13.3 Concord Biotech Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
2.13.4 Concord Biotech Autoimmune Hemolytic Anemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Concord Biotech Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Autoimmune Hemolytic Anemia Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Autoimmune Hemolytic Anemia Therapeutics Players Market Share
3.2.2 Top 10 Autoimmune Hemolytic Anemia Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Autoimmune Hemolytic Anemia Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Autoimmune Hemolytic Anemia Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Autoimmune Hemolytic Anemia Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Autoimmune Hemolytic Anemia Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2026)
6.2 North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2026)
6.3 North America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country
6.3.1 North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2026)
7.2 Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2026)
7.3 Europe Autoimmune Hemolytic Anemia Therapeutics Market Size by Country
7.3.1 Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Size by Region
8.3.1 Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Region (2016-2026)
8.3.2 China Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2026)
9.2 South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2026)
9.3 South America Autoimmune Hemolytic Anemia Therapeutics Market Size by Country
9.3.1 South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Market Size by Country
10.3.1 Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Autoimmune Hemolytic Anemia Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Autoimmune Hemolytic Anemia Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Autoimmune Hemolytic Anemia Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Autoimmune Hemolytic Anemia Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Amneal Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 7. Amneal Pharmaceuticals Inc Major Business
Table 8. Amneal Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 9. Amneal Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Baxter International Inc Corporate Information, Head Office, and Major Competitors
Table 11. Baxter International Inc Major Business
Table 12. Baxter International Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 13. Baxter International Inc Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 15. F. Hoffmann-La Roche Ltd Major Business
Table 16. F. Hoffmann-La Roche Ltd Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 17. F. Hoffmann-La Roche Ltd Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Incyte Corp Corporate Information, Head Office, and Major Competitors
Table 19. Incyte Corp Major Business
Table 20. Incyte Corp Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 21. Incyte Corp Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Kezar Life Sciences Inc Corporate Information, Head Office, and Major Competitors
Table 23. Kezar Life Sciences Inc Major Business
Table 24. Kezar Life Sciences Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 25. Kezar Life Sciences Inc Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 27. Pfizer Inc Major Business
Table 28. Pfizer Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 29. Pfizer Inc Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Rigel Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 31. Rigel Pharmaceuticals Inc Major Business
Table 32. Rigel Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 33. Rigel Pharmaceuticals Inc Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 37. Sanofi Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Teva Pharmaceutical Industries Ltd Corporate Information, Head Office, and Major Competitors
Table 39. Teva Pharmaceutical Industries Ltd Major Business
Table 40. Teva Pharmaceutical Industries Ltd Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 41. Teva Pharmaceutical Industries Ltd Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Horizo​​n Corporate Information, Head Office, and Major Competitors
Table 43. Horizo​​n Major Business
Table 44. Horizo​​n Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 45. Horizo​​n Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Genentech Corporate Information, Head Office, and Major Competitors
Table 47. Genentech Major Business
Table 48. Genentech Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 49. Genentech Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Zydus Cadila Corporate Information, Head Office, and Major Competitors
Table 51. Zydus Cadila Major Business
Table 52. Zydus Cadila Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 53. Zydus Cadila Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Concord Biotech Corporate Information, Head Office, and Major Competitors
Table 55. Concord Biotech Major Business
Table 56. Concord Biotech Autoimmune Hemolytic Anemia Therapeutics Product and Solutions
Table 57. Concord Biotech Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Global Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 59. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Players (2019-2021)
Table 60. Breakdown of Autoimmune Hemolytic Anemia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Autoimmune Hemolytic Anemia Therapeutics Players Head Office, Products and Services Provided
Table 62. Autoimmune Hemolytic Anemia Therapeutics Mergers & Acquisitions in the Past Five Years
Table 63. Autoimmune Hemolytic Anemia Therapeutics New Entrants and Expansion Plans
Table 64. Global Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 65. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Type (2016-2021)
Table 66. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Forecast by Type (2021-2026)
Table 67. Global Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2021)
Table 68. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Forecast by Application (2021-2026)
Table 69. North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 74. North America Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 75. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 76. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 77. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 78. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 79. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 80. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 81. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 82. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 84. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 86. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 87. South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 88. South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 89. South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 90. South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 91. South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 92. South America Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 93. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 94. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 96. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 98. Middle East & Africa Autoimmune Hemolytic Anemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Autoimmune Hemolytic Anemia Therapeutics Picture
Figure 2. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Type in 2020
Figure 3. Corticosteroids
Figure 4. Monoclonal Antibodies
Figure 5. Others
Figure 6. Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Application in 2020
Figure 7. Hospital Pharmacies Picture
Figure 8. Retail Pharmacies Picture
Figure 9. Online Pharmacies Picture
Figure 10. Global Autoimmune Hemolytic Anemia Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Autoimmune Hemolytic Anemia Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Autoimmune Hemolytic Anemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Autoimmune Hemolytic Anemia Therapeutics Market Drivers
Figure 20. Autoimmune Hemolytic Anemia Therapeutics Market Restraints
Figure 21. Autoimmune Hemolytic Anemia Therapeutics Market Trends
Figure 22. Amneal Pharmaceuticals Inc Recent Developments and Future Plans
Figure 23. Baxter International Inc Recent Developments and Future Plans
Figure 24. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 25. Incyte Corp Recent Developments and Future Plans
Figure 26. Kezar Life Sciences Inc Recent Developments and Future Plans
Figure 27. Pfizer Inc Recent Developments and Future Plans
Figure 28. Rigel Pharmaceuticals Inc Recent Developments and Future Plans
Figure 29. Sanofi Recent Developments and Future Plans
Figure 30. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Figure 31. Horizo​​n Recent Developments and Future Plans
Figure 32. Genentech Recent Developments and Future Plans
Figure 33. Zydus Cadila Recent Developments and Future Plans
Figure 34. Concord Biotech Recent Developments and Future Plans
Figure 35. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Players in 2020
Figure 36. Autoimmune Hemolytic Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 37. Global Top 3 Players Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share in 2020
Figure 38. Global Top 10 Players Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share in 2020
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 40. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Type in 2020
Figure 41. Global Autoimmune Hemolytic Anemia Therapeutics Market Share Forecast by Type (2021-2026)
Figure 42. Global Autoimmune Hemolytic Anemia Therapeutics Revenue Share by Application in 2020
Figure 43. Global Autoimmune Hemolytic Anemia Therapeutics Market Share Forecast by Application (2021-2026)
Figure 44. North America Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 45. North America Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 46. North America Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 47. United States Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Canada Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Mexico Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Europe Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 51. Europe Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 52. Europe Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 53. Germany Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 59. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 61. China Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South Korea Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 68. South America Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 69. South America Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East and Africa Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 73. Middle East and Africa Autoimmune Hemolytic Anemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 74. Middle East and Africa Autoimmune Hemolytic Anemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. UAE Autoimmune Hemolytic Anemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source

---